Finland Seeks to Lead the Silver Economy Charge

As Nordic economy faces an ageing population, its businesses seek an opportunity

Europe is slowly and steadily getting older. Today there are 3.3 people of working age — 15 to 64 — for every one over 65; by 2070 it will be just 2, according to the European Commission.

The conventional way to look at this ageing is as a huge challenge to society, public services, and governments. An older population will put immense strain on everything from healthcare to pensions. There is little sign that Europe is well prepared.

However, there is another way of viewing the shifting demographics — as an untapped opportunity for businesses to reach a new breed of customer. There has been some talk of the so-called “silver economy” but there are finally small signs that the topic is being taken more seriously in boardrooms and cabinets.

There is little surprise that one of the countries taking it most seriously is Finland. The Nordic country of 5.5m people has the most rapidly-ageing population among large EU countries and was once only behind Japan globally. Its previous centre-right government collapsed in March due to its inability to pass a healthcare reform necessary to offset the impact of an ageing population.

Finland has been thinking for decades about the effect of having an increasing number of elderly citizens. But it is only recently that business has caught up. Esko Aho, who is both a former senior executive at Nokia and ex-Finnish prime minister, is one of the movers behind a new high-level forum on the silver economy to be held in Helsinki next month.

The forum — tied into Finland’s EU presidency that starts just days earlier — brings together business leaders such as senior executives from pharmaceuticals group Bayer, insurer Aegon, and furniture retailer Ikea with policymakers including the mayor of Manchester and the president of the Federal Reserve of Kansas City.

“If we don’t do anything it will stay a problem, not an opportunity,” said Mr Aho. “But if we are able to meet these challenges, there will not be much harm for society. Maybe the opposite — people will live longer and be happier.”

He espouses the catchphrase of many in this area: “silver is the next green”. The parallels with climate change may be inexact but some are striking.

The changes from ageing are perhaps not visible day to day but over several years they certainly are. As with the early days of renewable energy, there is a lack of both a market and investors with both needing the other. “It’s like sustainability — it’s not enough to change something in the field of climate change; you have to change mindsets and the fundamental set-up of the economic system,” said Mr Aho.

For business, the size of the market is apparent but seizing the opportunity is harder. A study from last year estimated the value of the silver economy in Europe — defined as the spending by the population aged over 50 on goods and services — is €3.7tn and is expected to grow to €5.7tn by 2025, according to a European Commission study.

Some companies are an obvious fit with an ageing population. Bayer, the German pharmaceuticals group, is sending both its chief executive Werner Baumann and chief medical officer Michael Devoy to Helsinki. “As we continue to see rapidly ageing populations around the world, effectively tackling and managing age-related illnesses have become pivotal. We have to focus on addressing these unmet needs,” said Mr Devoy.

But there is an opportunity for businesses not just to provide what older people need but also what they want. Technology and entertainment groups, financial services companies, home designers, travel businesses — all are not obviously connected to ageing but each one could adapt their products better to better serve older customers. Some start-ups are active in the area but few have shot to prominence yet. Experts believe entrepreneurs and venture capitalists need to take the silver economy more seriously.

Mr Aho’s aims for the first meeting are relatively modest — to start dialogue between companies and governments while bringing the opportunities arising from an ageing population to a global audience. But as much of Europe and Asia face rapidly ageing populations over this century the need for businesses to come up with their own strategy for dealing with it will grow and grow.

Source: Financial Times

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.